Menu
Search
|

Menu

Close
X

Amphastar Pharmaceuticals Inc AMPH.OQ (NASDAQ Stock Exchange Global Select Market)

21.52 USD
-0.10 (-0.46%)
As of Sep 13
Previous Close 21.62
Open 21.72
Volume 76,037
3m Avg Volume 92,400
Today’s High 21.97
Today’s Low 21.36
52 Week High 25.42
52 Week Low 17.71
Shares Outstanding (mil) 47.07
Market Capitalization (mil) 937.07
Forward P/E 443.43
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
80
FY18
295
FY17
240
FY16
255
EPS (USD)
FY19
0.017
FY18
-0.124
FY17
0.078
FY16
0.209
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
443.43
33.85
Price to Sales (TTM)
vs sector
2.96
7.90
Price to Book (MRQ)
vs sector
2.80
4.38
Price to Cash Flow (TTM)
vs sector
60.73
23.70
Total Debt to Equity (MRQ)
vs sector
14.50
17.64
LT Debt to Equity (MRQ)
vs sector
9.25
12.61
Return on Investment (TTM)
vs sector
-0.44
12.69
Return on Equity (TTM)
vs sector
0.69
17.13

EXECUTIVE LEADERSHIP

Mary Luo
Chief Operating Officer, Chief Scientist and Chairman of the Board, Since 2005
Salary: $718,001.00
Bonus: $424,464.00
Jason Shandell
President, General Counsel, Director, Since 2017
Salary: $574,001.00
Bonus: $311,818.00
Jack Zhang
Chief Executive Officer, Chief Scientific Officer, Director, Since 2013
Salary: $880,000.00
Bonus: $668,454.00
William Peters
Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc., Since 2016
Salary: --
Bonus: --
Rong Zhou
Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc., Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11570 6th St
RANCHO CUCAMONGA   CA   91730-6025

Phone: +1909.9809484

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

SPONSORED STORIES